SAN CARLOS, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that preclinical data evaluating the mechanism of action and therapeutic potential of NU206 (R-spondin1) for chemotherapy or radiation-induced oral mucositis, and preclinical data evaluating recombinant nematode anticoagulant protein c2 (rNAPc2) in mouse models of colorectal cancer, will be presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA, April 12-16, 2008.
The presentation details are as follows:
Date/Time: Sunday, April 13, 2008, 1:00 - 5:00 p.m. PT
Poster Title (#1495): R-spondin1 protects mice from chemotherapy or radiation-induced oral mucositis by activating canonical Wnt/beta-catenin pathway
Location: Poster Board #2, Section 32, Exhibit Hall B-F, San Diego Convention Center
Date/Time: Wednesday, April 16, 2008, 8:00 a.m. - 12:00 p.m. PT
Poster Title (#5698): rNAPc2 inhibits colorectal cancer in mouse models through tissue factor
Location: Poster Board #11, Section 31, Exhibit Hall B-F, San Diego Convention Center
Nuvelo, Inc. is dedicated to improving the lives of patients through
the discovery, development and commercialization of novel drugs for acute
cardiovascular disease, cancer and other debilitating medical conditions.
Nuvelo's development pipeline includes NU172, a direct thrombin inhibitor
in Phase 1 development for use as a potential short-acting anticoagulant
during medical or surgical procedures; and preclinical candidate NU206, a
Wnt pathway modulator for the potential treatment of chemotherapy/radiation
therapy-induced mucositis and inflammatory bowel disease. In addition,
Nuvelo is pur
|SOURCE Nuvelo, Inc.|
Copyright©2008 PR Newswire.
All rights reserved